Wells Fargo & Company MN Acquires 849,233 Shares of TG Therapeutics Inc common stock (TGTX)

Wells Fargo & Company MN raised its holdings in TG Therapeutics Inc common stock (NASDAQ:TGTX) by 2,148.1% during the second quarter, HoldingsChannel reports. The institutional investor owned 888,768 shares of the biopharmaceutical company’s stock after buying an additional 849,233 shares during the quarter. Wells Fargo & Company MN’s holdings in TG Therapeutics Inc common stock were worth $11,686,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Xact Kapitalforvaltning AB bought a new position in shares of TG Therapeutics Inc common stock in the second quarter valued at $139,000. Cubist Systematic Strategies LLC bought a new position in shares of TG Therapeutics Inc common stock in the first quarter valued at $176,000. North Star Investment Management Corp. bought a new position in shares of TG Therapeutics Inc common stock in the second quarter valued at $276,000. Barclays PLC lifted its stake in shares of TG Therapeutics Inc common stock by 107.1% in the first quarter. Barclays PLC now owns 23,304 shares of the biopharmaceutical company’s stock valued at $331,000 after buying an additional 12,053 shares in the last quarter. Finally, Federated Investors Inc. PA bought a new position in shares of TG Therapeutics Inc common stock in the first quarter valued at $817,000. 48.99% of the stock is currently owned by hedge funds and other institutional investors.

In other news, CFO Sean A. Power sold 47,191 shares of the stock in a transaction dated Tuesday, July 3rd. The shares were sold at an average price of $13.21, for a total value of $623,393.11. Following the completion of the sale, the chief financial officer now owns 473,267 shares in the company, valued at $6,251,857.07. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director William James Kennedy sold 25,071 shares of the stock in a transaction dated Thursday, June 14th. The shares were sold at an average price of $13.45, for a total transaction of $337,204.95. The disclosure for this sale can be found here. Corporate insiders own 15.10% of the company’s stock.

Shares of TGTX stock traded down $0.10 on Friday, hitting $11.80. The stock had a trading volume of 1,234 shares, compared to its average volume of 866,122. The company has a market cap of $1.03 billion, a P/E ratio of -6.20 and a beta of 1.16. TG Therapeutics Inc common stock has a 12-month low of $7.25 and a 12-month high of $17.35.

TG Therapeutics Inc common stock (NASDAQ:TGTX) last announced its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics Inc common stock had a negative net margin of 97,412.51% and a negative return on equity of 177.79%. equities research analysts predict that TG Therapeutics Inc common stock will post -2.19 earnings per share for the current year.

Several analysts have recently commented on the stock. BidaskClub downgraded shares of TG Therapeutics Inc common stock from a “hold” rating to a “sell” rating in a report on Tuesday, June 12th. Zacks Investment Research upgraded shares of TG Therapeutics Inc common stock from a “sell” rating to a “hold” rating in a report on Thursday, July 26th. HC Wainwright reiterated a “buy” rating and issued a $38.00 target price on shares of TG Therapeutics Inc common stock in a report on Tuesday, August 7th. Finally, ValuEngine upgraded shares of TG Therapeutics Inc common stock from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $31.00.

About TG Therapeutics Inc common stock

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Read More: NASDAQ

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics Inc common stock (NASDAQ:TGTX).

Institutional Ownership by Quarter for TG Therapeutics Inc common stock (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc common stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc common stock and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply